Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03845166
What this trial is testing

XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Who this might be right for
Neoplasm MalignantRenal Cell CarcinomaHormone Receptor Positive Breast Carcinoma+2 more
Exelixis 325
Testing effectiveness (Phase 2)Looking for participantsNCT05190094
What this trial is testing

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

Who this might be right for
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
International Cancer Research Group, United Arab Emirates 80
Large-scale testing (Phase 3)Active Not RecruitingNCT02763566
What this trial is testing

Abemaciclib (LY2835219) in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 463
Not applicableLooking for participantsNCT06734533
What this trial is testing

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Who this might be right for
HR+ Breast Cancer
Hunan Cancer Hospital 80
Large-scale testing (Phase 3)UnknownNCT04337658
What this trial is testing

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 493
Large-scale testing (Phase 3)UnknownNCT03423199
What this trial is testing

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Who this might be right for
Breast Neoplasms
National Cancer Center, Japan 180
Post-approval studies (Phase 4)Study completedNCT02248571
What this trial is testing

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Who this might be right for
Breast Cancer RecurrentHER2/Neu-negative Carcinoma of BreastHormone Receptor Positive Malignant Neoplasm of Breast
iOMEDICO AG 85
Testing effectiveness (Phase 2)Study completedNCT01004081
What this trial is testing

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Who this might be right for
Breast Cancer
Biogen 54
Testing effectiveness (Phase 2)Looking for participantsNCT05608252
What this trial is testing

VS-6766+Abema+Fulv in Met HR+/HER- BC

Who this might be right for
Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks 63
Post-approval studies (Phase 4)Active Not RecruitingNCT05161195
What this trial is testing

Roll-over Study to Allow Continued Access to Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 134
Not applicableUnknownNCT05287139
What this trial is testing

QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.

Who this might be right for
Quality of LifeBreast Neoplasm Female
Beneficência Portuguesa de São Paulo 202